CSF2 and B-cell chronic lymphocytic leukemia: EBV, owing to its specificity for B cells, has been utilized to deliver (granulocyte-macrophage colony-stimulating factor) GM-CSF therapy to patients of B-cell chronic lymphocytic leukemia (B-CLL) [101].